Fwd: Nanoparticles Prevent Bone Cancer, Strengthen Bones; Actavis Closes $28B Forest Deal

Sent from my iPad

Begin forwarded message:

From: Kent Castle <kent.d.castle@hotmail.com>
Date: July 1, 2014 3:36:11 PM CDT
To: Patterson James <w8ljz@aol.com>, Bogan Carole <bcbogan@earthlink.net>, Chamberlain Sharon <sharon.m.chamberlain@saic.com>, Astrology Valkyrie <astrogoddess@valkyrieastrology.com>, Madsen Ron <ronstar@pdq.net>, Martin Bobby <bobbygmartin1938@gmail.com>, Lozano Marianne <kemahsabe@comcast.net>, Matthews-Schmidt Linda <linda.j.matthews-schmidt@nasa.gov>, Kelley Mary <mary.n.kelley@nasa.gov>
Subject: FW: Nanoparticles Prevent Bone Cancer, Strengthen Bones; Actavis Closes $28B Forest Deal

 

---

From: reply@mail.dddmag.com
To: KENT.D.CASTLE@HOTMAIL.COM
Subject: Nanoparticles Prevent Bone Cancer, Strengthen Bones; Actavis Closes $28B Forest Deal
Date: Tue, 1 Jul 2014 09:46:08 -0600

Amgen's Leukemia Drug Gets FDA Breakthrough Designation; GlycoVaxyn Kicks Off Trial of UTI Vaccine

View this email in your browser. JULY 01   IN THIS ISSUE   NEWS     Actavis Closes $28B Forest Deal     NEWS     Amgen's Leukemia Drug Gets FDA Breakthrough Designation     NEWS     GlycoVaxyn Kicks Off Trial of UTI Vaccine     NEWS     Ipsen Applies for US, EU GEP-NET Drug Marketing Authorizations     NEWS     CTI BioPharma Wraps Up Recruitment in Pivotal Trial of Myelofibrosis Drug   Improve Data Reproducibility with Gilson Gilson enables scientists to simplify sample preparation; we specialize in pipettes and automated solutions built upon your applications. New PIPETMAX® brings reproducibility to qPCR, NGS and cell-based assays allowing you to accelerate the pace of your verifiable science. LEARN MORE     FEATURED STORY Nanoparticles Prevent Bone Cancer, Strengthen Bones     A research collaboration between Dana-Farber Cancer Institute and Brigham and Women's Hospital and has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent bone cancer progression. Read more... Share FULL STORY     NEWS Actavis Closes $28B Forest Deal Actavis has completed its $28 billion acquisition of fellow drugmaker Forest Laboratories, and the leader of the acquired company - Brenton Saunders - is now the CEO of Actavis, and former Actavis Chairman and CEO Paul Bisaro will become executive chairman. Read more... FULL STORY     NEWS Amgen's Leukemia Drug Gets FDA Breakthrough Designation Amgen announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to investigational bispecific T cell engager antibody blinatumomab, for adults with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia, a rapidly progressing cancer of the blood and bone marrow. Read more... FULL STORY     NEWS GlycoVaxyn Kicks Off Trial of UTI Vaccine GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, announced the initiation of a Phase 1 clinical trial of a candidate vaccine to prevent infections caused by Extra-intestinal Pathogenic Escherichia coli (ExPEC), such as urinary tract infections (UTIs). Read more... FULL STORY     NEWS Ipsen Applies for US, EU GEP-NET Drug Marketing Authorizations Ipsen announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Somatuline Depot 120 mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Read more... FULL STORY     NEWS CTI BioPharma Wraps Up Recruitment in Pivotal Trial of Myelofibrosis Drug CTI BioPharma Corp. announced that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, without exclusion for low platelet counts . Read more... FULL STORY   SUBSCRIBE • UNSUBSCRIBE • ABOUT US • ADVERTISE This email was sent by: Drug Discovery & Development 100 Enterprise Drive - Suite 600 - Rockaway, NJ 07866-2129 We respect your right to privacy - click here to view our policy. ©2014 Drug Discovery & Development. All rights reserved.